HPV - Immune response to infection and vaccination

Infectious Agents and Cancer

Volumn 5, Issue 1, 2010, Pages

  Stanley, Margaret ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COAT PROTEIN; WART VIRUS VACCINE;

HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 6; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROCONVERSION; VACCINATION; VERRUCA VULGARIS; VIRUS ENTRY; VIRUS STRAIN; WART VIRUS;

EID: 77957997448     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-5-19     Document Type: Review

References (50)

1. Condylomatous lesions of the cervix and vagina. I. Cytologic patterns. A Meisels R Fortin, Acta Cytol 1976 20 505 509 1069445
2. Condylomatous lesions of the cervix. II. Cytologic, colposcopic and histopathologic study. A Meisels R Fortin M Roy, Acta Cytol 1977 21 379 390 268117
3. Partial characterization of viral DNA from human genital warts (Condylomata acuminata). L Gissmann H zur Hausen, Int J Cancer 1980 25 605 609 10.1002/ijc.2910250509 6246010
4. Molecular cloning and characterization of human papilloma virus DNA derived from a laryngeal papilloma. L Gissmann V Diehl HJ Schultz-Coulon HH zur, J Virol 1982 44 393 400 6292500
5. A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. M Durst L Gissmann H Ikenberg H zur Hausen, Proc Natl Acad Sci USA 1983 80 3812 3815 10.1073/pnas.80.12.3812 6304740
6. A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. M Boshart L Gissmann H Ikenberg A Kleinheinz W Scheurlen H zur Hausen, EMBO J 1984 3 1151 1157 6329740
7. Chapter 1: HPV in the etiology of human cancer. N Munoz X Castellsague AB de Gonzalez L Gissmann, Vaccine 2006 24 Suppl 3 3 1-S310
8. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. SK Kjaer TN Tran P Sparen L Tryggvadottir C Munk E Dasbach,, et al. J Infect Dis 2007 196 1447 1454 10.1086/522863 18008222
9. Epidemiology of recurrent respiratory papillomatosis. DA Larson CS Derkay, APMIS 2010 118 450 454 10.1111/j.1600-0463.2010.02619.x 20553527
10. Recurrent respiratory papillomatosis: a review. CS Derkay B Wiatrak, Laryngoscope 2008 118 1236 1247 10.1097/MLG.0b013e31816a7135 18496162
11. Chapter 5: Updating the natural history of HPV and anogenital cancer. AB Moscicki M Schiffman S Kjaer LL Villa, Vaccine 2006 24 Suppl 3 3-42 S3/51
12. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. J Peto C Gilham J Deacon C Taylor C Evans W Binns,, et al. Br J Cancer 2004 91 942 953 15292939
13. Epidemiology of genital human papillomavirus infection. L Koutsky, Am J Med 1997 102 3 8 10.1016/S0002-9343(97)00177-0 9217656 (Pubitemid 127695953)
14. Immune responses to human papillomavirus. M Stanley, Vaccine 2006 24 Suppl 1 16 S22 10.1016/j.vaccine.2005.09.002 16219398
15. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. YL Woo M van den Hende JC Sterling N Coleman RA Crawford KM Kwappenberg,, et al. Int J Cancer 2010 126 133 141 10.1002/ijc.24804 19645010
16. The papillomavirus life cycle. J Doorbar, J Clin Virol 2005 32 Suppl 1 7 15 10.1016/j.jcv.2004.12.006 15753007
17. Molecular biology of human papillomavirus infection and cervical cancer. J Doorbar, Clin Sci (Lond) 2006 110 525 541 10.1042/CS20050369 16597322
18. Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. MR Pett MT Herdman RD Palmer GS Yeo MK Shivji MA Stanley,, et al. Proc Natl Acad Sci USA 2006 103 3822 3827 10.1073/pnas.0600078103 16505361
19. Mechanisms used by human papillomaviruses to escape the host immune response. S Kanodia LM Fahey WM Kast, Curr Cancer Drug Targets 2007 7 79 89 10.2174/156800907780006869 17305480
20. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. UA Hasan E Bates F Takeshita A Biliato R Accardi V Bouvard,, et al. J Immunol 2007 178 3186 3197 17312167
21. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. JJ Carter LA Koutsky JP Hughes SK Lee J Kuypers N Kiviat,, et al. J Infect Dis 2000 181 1911 1919 10.1086/315498 10837170
22. Stability over time of serum antibody levels to human papillomavirus type 16. V af Geijersstam M Kibur Z Wang P Koskela E Pukkala J Schiller,, et al. J Infect Dis 1998 177 1710 1714 10.1086/517428 9607854
23. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. SE Olsson SK Kjaer K Sigurdsson OE Iversen M Hernandez-Avila CM Wheeler,, et al. Hum Vaccin 2009 5 696 704 10.4161/hv.5.10.9515 19855170
24. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. R Kirnbauer F Booy N Cheng DR Lowy JT Schiller, Proc Natl Acad Sci USA 1992 89 12180 12184 10.1073/pnas.89.24.12180 1334560
25. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. J Zhou XY Sun DJ Stenzel IH Frazer, Virology 1991 185 251 257 10.1016/0042-6822(91) 90772-4 1656586
26. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. F Breitburd R Kirnbauer NL Hubbert B Nonnenmacher C Trin-Dinh-Desmarquet G Orth,, et al. J Virol 1995 69 3959 3963 7745754
27. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. JA Suzich SJ Ghim FJ Palmer-Hill WI White JK Tamura JA Bell,, et al. Proc Natl Acad Sci USA 1995 92 11553 11557 10.1073/pnas.92.25.11553 8524802
28. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. SK Kjaer K Sigurdsson OE Iversen M Hernandez-Avila CM Wheeler G Perez,, et al. Cancer Prev Res (Phila) 2009 2 868 878 10.1158/1940-6207.CAPR-09-0031 19789295
29. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. J Paavonen P Naud J Salmeron CM Wheeler SN Chow D Apter,, et al. Lancet 2009 374 301 314 10.1016/S0140-6736(09)61248-4 19586656
30. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. J Dillner SK Kjaer CM Wheeler K Sigurdsson OE Iversen M Hernandez-Avila,, et al. BMJ 2010 341 3493 10.1136/bmj.c5128 20647284
31. Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women. CK Fairley JS Hocking LC Gurrin MY Chen B Donovan CS Bradshaw, Sex Transm Infect 2009 85 499 502 10.1136/sti.2009.037788 19837728
32. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. DM Harper EL Franco C Wheeler DG Ferris D Jenkins A Schuind,, et al. Lancet 2004 364 1757 1765 10.1016/S0140-6736(04)17398-4 15541448
33. Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. LL Villa KA Ault AR Giuliano RL Costa CA Petta RP Andrade,, et al. Vaccine 2006 24 5571 5583 10.1016/j.vaccine.2006.04.068 16753240
34. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. N De Carvalho J Teixeira CM Roteli-Martins P Naud BP De T Zahaf,, et al. Vaccine 2010 28 6247 6255 10.1016/j.vaccine.2010.07.007 20643092
35. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. A Rowhani-Rahbar C Mao JP Hughes FB Alvarez JT Bryan SE Hawes,, et al. Vaccine 2009 27 5612 5619 10.1016/j.vaccine.2009.07.027 19647066
36. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. MP David K Van Herck K Hardt F Tibaldi G Dubin D Descamps,, et al. Gynecol Oncol 2009 115 1 S6 10.1016/j.ygyno.2009.01.011 19217149
37. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. C Fraser JE Tomassini L Xi G Golm M Watson AR Giuliano,, et al. Vaccine 2007 25 4324 4333 10.1016/j.vaccine.2007.02.069 17445955
38. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. JF Smith M Brownlow M Brown R Kowalski MT Esser W Ruiz,, et al. Hum Vaccin 2007 3 109 115 17611417
39. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. JG Dauner Y Pan A Hildesheim C Harro LA Pinto, Vaccine 2010 28 5407 5413 10.1016/j.vaccine.2010.06.018 20591543
40. Papillomavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. P Lenz DR Lowy JT Schiller, Eur J Immunol 2005 35 1548 1556 10.1002/eji.200425547 15832296
41. Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. R Yang FM Murillo KY Lin WH Yutzy S Uematsu K Takeda,, et al. J Immunol 2004 173 2624 2631 15294979
42. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. CD Harro YY Pang RB Roden A Hildesheim Z Wang MJ Reynolds,, et al. J Natl Cancer Inst 2001 93 284 292 10.1093/jnci/93.4.284 11181775
43. Maintenance of serological memory. J Wrammert R Ahmed, Biol Chem 2008 389 537 539 10.1515/BC.2008.066 18953719
44. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. SE Olsson LL Villa RL Costa CA Petta RP Andrade C Malm,, et al. Vaccine 2007 25 4931 4939 10.1016/j.vaccine.2007.03.049 17499406
45. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. SL Giannini E Hanon P Moris MM Van S Morel F Dessy,, et al. Vaccine 2006 24 5937 5949 10.1016/j.vaccine.2006.06.005 16828940
46. Human B cell memory. A Lanzavecchia F Sallusto, Curr Opin Immunol 2009 21 298 304 10.1016/j.coi.2009.05.019 19497721
47. Structure, attachment and entry of polyoma- and papillomaviruses. M Sapp PM Day, Virology 2009 384 400 409 10.1016/j.virol.2008.12.022 19157477
48. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. JN Roberts CB Buck CD Thompson R Kines M Bernardo PL Choyke,, et al. Nat Med 2007 13 857 861 10.1038/nm1598 17603495
49. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. RC Kines CD Thompson DR Lowy JT Schiller PM Day, Proc Natl Acad Sci USA 2009 106 20458 20463 10.1073/pnas.0908502106 19920181
50. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. PM Day CD Thompson CB Buck YY Pang DR Lowy JT Schiller, J Virol 2007 81 8784 8792 10.1128/JVI.00552-07 17553881